Jaguar Health Highlights Key 2025 Developments for Crofelemer

Jaguar Health, Inc. shared anticipated developments for 2025 regarding crofelemer, an FDA-approved plant-based drug. Primarily targeting rare diseases and cancer therapy-related diarrhea, crofelemer is the only oral medication approved under the FDA's Botanical Guidance.

Recent data from trials in the UAE showed promising reductions in parenteral support needs among pediatric patients with rare intestinal conditions. These results suggest potential regulatory advancements in both the EU and US for crofelemer.

In the cancer therapy sector, a Type C meeting with the FDA is scheduled for Q2 2025 following noteworthy results in breast cancer patient trials. The goal is to expedite crofelemer's availability for this subgroup.